RE: Blue5 May 2020 14:13
I wonder if they are using Avactas Affirmer, Antigens rather than antibodies .
There are high hopes for an experimental vaccine for COVID-19 being developed by the University of Queensland (UQ) in Brisbane. Cytiva, formerly known as GE Healthcare Life Sciences, is developing a specific prototype affinity resin and providing technology and services to support the efforts of those scientists. Currently in pre-clinical testing, the vaccine is being prepared to enter clinical trials.
Cytiva will bring manufacturing support and technology to the overall program, including supporting the making of clinical trial phase I vaccine at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), an Australian government scientific research group. Cytiva will also create a specific prototype affinity resin for vaccine purification at its site in Uppsala and support scale up with planning underway for phase II material manufacturing through its Fast Trak center at Locke Drive, Marlborough.
Professor Trent Munro, Director National Biologics Facility & Program Director Rapid Response Vaccine Pipeline at UQ, says: “The Cytiva team has been amazing in understanding our needs and offering any and all resources to push this critical program forward. We look forward to building the partnership over the coming months.”
Emmanuel Ligner, President, Cytiva, says: “The COVID-19 crisis has brought together the scientific community like never before. Our global team is helping to accelerate the work of vaccine researchers like those at the University of Queensland, as well as diagnostic developers, to bring access to much-needed solutions.”